Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...

CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...